Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof

Abstract

This invention provides the use of a microorganism capable of improving both lipid metabolism and sugar metabolism. Specifically, the invention relates to: a lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell selected from bacteria belonging to the genus Lactobacillus and the genus Bifidobacterium , a treated product of the bacterial cell, or a mixture thereof, having dual-agonistic activities to peroxisome proliferator activated receptor (PPAR)α and peroxisome proliferator activated receptor (PPAR)γ; to a food or a beverage comprising the improver; and to a pharmaceutical composition comprising the improver.

1 . A bacterial cell or a treated product thereof having dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR)α and a peroxisome proliferator activated receptor (PPAR)γ. 
     
     
         2 . The bacterial cell or the treated product thereof according to  claim 1 , wherein the PPARα activity is 70 or more relative to negative control activity of 0 and positive control activity of 100 as measured by PPARα reporter assay and the PPARγ ligand activity shows positive exceeding 0 relative to negative control activity of 0 and positive control activity of 100 as measured by PPARγ reporter assay. 
     
     
         3 . The bacterial cell or the treated product thereof according to  claim 1  or  2 , wherein the bacterial cell belongs to  Lactobacillus amylovorus, Lactobacillus gasseri, Bifidobacterium infantis, Bifidobacterium adolescentis , or  Bifidobacterium breve.   
     
     
         4 . The bacterial cell or the treated product thereof according to any one of  claims 1  to  3 , wherein the bacterial cell is  Lactobacillus amylovorus  CP1563 strain (Accession Number FERM BP-11255) or  Lactobacillus amylovorus  CP1562 strain (Accession Number FERM BP-11379) or a mutant or bred strain thereof, or a mutant or bred strain of  Lactobacillus gasseri  CP2305 strain (Accession Number FERM BP-11331). 
     
     
         5 . The treated product of bacterial cell according to any one of  claims 1  to  4 , which is a destructed product of the bacterial cell, an extracted product of the bacterial cell, or a dried product thereof. 
     
     
         6 . A lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell, a treated product thereof, or a mixture thereof having dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR)α and a peroxisome proliferator activated receptor (PPAR)γ. 
     
     
         7 . A lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell selected from bacteria belonging to the genus  Lactobacillus  and the genus  Bifidobacterium , a treated product thereof, or a mixture thereof having dual-agonistic activities on a peroxisome proliferator activated receptor (PPAR)α and a peroxisome proliferator activated receptor (PPAR)γ. 
     
     
         8 . The lipid metabolism and/or sugar metabolism improver according to  claim 6  or  7 , wherein the PPARα activity is 70 or more relative to negative control activity of 0 and positive control activity of 100 as measured by PPARα reporter assay and the PPARγ ligand activity shows positive exceeding 0 relative to negative control activity of 0 and positive control activity of 100 as measured by PPARγ reporter assay. 
     
     
         9 . The lipid metabolism and/or sugar metabolism improver according to any one of  claims 6  to  8 , wherein the bacterial cell belongs to  Lactobacillus amylovorus, Lactobacillus gasseri, Bifidobacterium infantis, Bifidobacterium adolescentis , or  Bifidobacterium breve.   
     
     
         10 . The lipid metabolism and/or sugar metabolism improver according to any one of  claims 6  to  9 , wherein the bacterial cell is  Lactobacillus amylovorus  CP1563 strain (Accession Number FERM BP-11255) or  Lactobacillus amylovorus  CP1562 strain (Accession Number FERM BP-11379),  Lactobacillus gasseri  CP2305 strain (Accession Number FERM BP-11331), or a mutant or bred strain thereof. 
     
     
         11 . The lipid metabolism and/or sugar metabolism improver according to any one of  claims 6  to  10 , wherein the treated product of bacterial cell is a destructed product of the bacterial cell, an extracted product of the bacterial cell, or a dried product thereof. 
     
     
         12 . The lipid metabolism and/or sugar metabolism improver according to any one of  claims 6  to  11 , which further comprises a carrier or an excipient used for foods or beverages or pharmaceutical drugs. 
     
     
         13 . A food or beverage comprising the lipid metabolism and/or sugar metabolism improver according to any one of  claims 6  to  12  as a food additive. 
     
     
         14 . The food or beverage according to  claim 13 , which is a functional food or health food for use in improving the lipid metabolism and/or sugar metabolism. 
     
     
         15 . A pharmaceutical composition for use in preventing, improving, or treating a lipid metabolism disorder and/or sugar metabolism disorder, comprising, as an active ingredient, the lipid metabolism and/or sugar metabolism improver according to any one of  claims 6  to  12 . 
     
     
         16 . A process for producing a food or beverage having a lipid metabolism and/or sugar metabolism improving effect, comprising adding the lipid metabolism and/or sugar metabolism improver according to any one of  claims 6  to  12  to a food or beverage. 
     
     
         17 . Use of  Lactobacillus amylovorus  CP1563 strain (Accession Number FERM BP-11255),  Lactobacillus amylovorus  CP1562 strain (Accession Number FERM BP-11379),  Lactobacillus gasseri  CP2305 strain (Accession Number FERM BP-11331), or a mutant or bred strain thereof, a treated product thereof, or a mixture thereof in the production of the lipid metabolism and/or sugar metabolism improver according to any one of  claims 6  to  12 . 
     
     
         18 .  Lactobacillus amylovorus  CP1563 strain (Accession Number FERM BP-11255) or  Lactobacillus amylovorus  CP1562 strain (Accession Number FERM BP-11379), or a mutant or bred strain thereof, or a mutant or bred strain of  Lactobacillus gasseri  CP2305 strain (Accession Number FERM BP-11331) for use in imparting a lipid metabolism and sugar metabolism improving action. 
     
     
         19 .  Lactobacillus amylovorus  CP1563 strain (Accession Number FERM BP-11255) or  Lactobacillus amylovorus  CP1562 strain (Accession Number FERM BP-11379) or a mutant or bred strain thereof, or a mutant or bred strain of  Lactobacillus gasseri  CP2305 strain (Accession Number FERM BP-11331). 
     
     
         20 . The bacterial cell or the treated product thereof according to  claim 1  or  2 , wherein the bacterial cell belongs to the genus  Lactobacillus  or the genus  Bifidobacterium.   
     
     
         21 . Use of the bacterial cell or the treated product thereof according to any one of  claims 1  to  5  for use in the production of a composition for improving lipid metabolism and/or sugar metabolism. 
     
     
         22 . Use of the bacterial cell or the treated product thereof according to any one of  claims 1  to  5  for use in the production of a composition for preventing lipid metabolism and/or sugar metabolism. 
     
     
         23 . The bacterial cell or the treated product thereof according to any one of  claims 1  to  5  for use in the production of a composition for improving lipid metabolism and/or sugar metabolism. 
     
     
         24 . The bacterial cell or the treated product thereof according to any one of  claims 1  to  5  for use in the production of a composition for preventing lipid metabolism and/or sugar metabolism. 
     
     
         25 . The bacterial cell or the treated product thereof according to any one of  claims 1  to  5  for use in the production of a composition for reducing subcutaneous fat and/or visceral fat. 
     
     
         26 . The bacterial cell or the treated product thereof according to any one of  claims 1  to  5  for use in the production of a composition for preventing accumulation of subcutaneous fat and/or visceral fat.